Cellsway
Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) from blood.
5 employees · est. 2020 · Ankara, United Kingdom
Cellsway is the older company (2020 vs 2025).
Side-by-Side Comparison
| Metric | Cellsway | MultivisionDx |
|---|---|---|
| Founded | ||
| Founded | 2020 older | 2025 |
| Headquarters | ||
| Headquarters | Ankara, United Kingdom | Helsinki, Finland |
| Employees | ||
| Employees | 5 | 3 |
| Industry | ||
| Industry | Biotechnology, Health Care | Not tracked yet |
| Funding Stage | ||
| Funding Stage | Unknown | Seed |
| Total Funding | ||
| Total Funding | $1.45M | Not tracked yet |
| Funding Rounds | ||
| Funding Rounds | 5 | 1 |
| Services | ||
| Services | CTC Enrichment Device, CTC Identification Panel, ER/PR/Her2 CTC Panel, PD-L1 CTC Panel | AI-powered decision-support tools, Personalized diagnosis, Treatment selection for solid cancer, Tumor profile generation |
| Target Customers | ||
| Target Customers | Cancer Patients, Oncologists, Clinical Laboratories, Research Institutions | Clinicians, Oncologists, Medical researchers, Healthcare institutions |
| Taxonomy | ||
| Taxonomy | Liquid Biopsy, Cancer Monitoring, Circulating Tumor Cells, CTC Detection, Microfluidics, Lab-on-a-chip, Biomedical Technology, Cancer Diagnostics, Cancer Research, Minimally Invasive Technology, Blood Sample Analysis, Deep-tech Startup, Oncology, Precision Medicine, Patent-pending Technology | AI-powered Decision-support Tools, Personalized Diagnosis, Solid Cancer, Computer Vision Technology, Tumor Profiling, Tumor Microenvironment, Patient-specific Tumor Profiles, Treatment Selection, Tumor Aggressiveness Assessment, Biomarker-discovery Platform, Composite Biomarker, Head-and-neck Cancer, Multidisciplinary Research, Proof-of-concept Study, Patent-pending Technology |
| Website | ||
| Website | cellsway.com | multivision.ai |
About Cellsway
Cellsway, a deep-tech start-up, is making strides in the Biotechnology and Health Care industries with its innovative approach to cancer monitoring. Founded in 2020 in the United Kingdom, this company aims to revolutionize cancer diagnostics through its flagship product: a liquid biopsy platform. T...
About MultivisionDx
MultivisionDx, an innovative player in the oncology diagnostics space, aims to revolutionize cancer care with its slogan, "Transforming cancer diagnostics". Founded in 2025 in Finland, the company leverages AI to enhance personalized cancer treatment through its decision-support tools. This cutting-...
We will tell you when either one moves
BounceWatch watches Cellsway and MultivisionDx for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Cellsway and MultivisionDx — by email.
Frequently Asked Questions
Compare Cellsway with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Cellsway on 2 Sep 2026, and MultivisionDx on 13 Nov 2025. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.